Cox proportional hazard regression analysis for rituximab and control groups
| Survival . | Rituximab . | Control . | ||||
|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | |
| FFS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 2.210 | 1.052-4.645 | .036 | 2.102 | 1.271-3.479 | .004 |
| Phenotype | ||||||
| ihc-defined GC or non-GC | 0.884 | 0.425-1.839 | .742 | 0.457 | 0.272-0.769 | .003 |
| OS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 2.736 | 1.076-6.957 | .035 | 3.533 | 2.011-6.208 | < .001 |
| Phenotype | ||||||
| ihc-defined GC or non-GC | 1.075 | 0.436-2.654 | .875 | 0.542 | 0.305-0.964 | .037 |
| Survival . | Rituximab . | Control . | ||||
|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | |
| FFS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 2.210 | 1.052-4.645 | .036 | 2.102 | 1.271-3.479 | .004 |
| Phenotype | ||||||
| ihc-defined GC or non-GC | 0.884 | 0.425-1.839 | .742 | 0.457 | 0.272-0.769 | .003 |
| OS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 2.736 | 1.076-6.957 | .035 | 3.533 | 2.011-6.208 | < .001 |
| Phenotype | ||||||
| ihc-defined GC or non-GC | 1.075 | 0.436-2.654 | .875 | 0.542 | 0.305-0.964 | .037 |
RR indicates relative risk; CI, confidence interval; IPI, higher IPI worse; ihc, immunohistochemically; and
GC vs non-GC, non-GC worse.